Clinical trial · Observational
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The explosion of novel therapies targeting tumor mutations or immune molecules requests to define or better characterize the mutational profiles of tumors that are none or insufficiently explored so far. This is particularly the case for tumors arising in immune-suppressed individuals or environments which have been poorly, if any, analyzed so far with modern molecular methods. The goal of the translational research program, Ideation, is to define novel biomarkers such as the tumor mutational profiling and immunomutanome in such contexts and to compare the results obtained to those observed in immune competent individuals. In addition, this approach will allow to characterize novel key non-invasive diagnostic and prognostic biomarkers such as circulating tumoral DNA and cells. Altogether results will provide novel biomarkers to better adapt therapeutic strategies in these cancers, to monitor response to treatment as well as to define new molecular targets of potential therapeutic strategies.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (7)
- label
- Non-Hodgkin-Lymphoma (after transplantation)
- description
- Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
- label
- Non-small cell lung cancer
- description
- Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
- label
- Primary Central Nervous System Lymphoma
- description
- Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
- label
- Gliomas
- description
- Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Followed at Pitié-Salpêtrière hospital, Tenon hospital, Henri Mondor hospital, Saint-Louis hospital or intercommunal hospital center of Créteil * Histological diagnosis confirmed of: * Non-small cell lung cancer (adenocarcinoma, squamous cell, large cells) related to HIV, or * Immunocompetent non-small cell lung cancer (adenocarcinoma, squamous cell, large cells), or * Non-Hodgkin's lymphoma (NHL): HIV-related NHL, post-transplant lymphoproliferation (LPT) according to WHO (World Health Organization) 2016 classification, primary CNS (central nervous system) lymphoma (LPS), or * Primary CNS lymphoma * Immunocompetent NHL: diffuse large B cell lymphoma (ABC or GC) * Glioma * Naïve cancer treatment (except for the specific case of gliomas with certain or possible activation of MAPK (Mitogen-activated protein kinases) and MMR (Mismatch Repair) inactivation). * Cancer undergoing surgery for excision or a large biopsy (pleural biopsy under video-thoracoscopy, mediastinoscopy, biopsy lymph node excision or cutaneous or cerebral metastasis). * For patients with NSCLC: hemoglobin level\> 9 g / dL; for patients with NHL or glioma: hemoglobin \> 7 g / dL. * Weight ≥ 48 kg. * Informed consent to participation signed before carrying out any specific procedure of the study. * Affiliation to the French social security system. Exclusion Criteria: * Other cancer than those in the study: * For NHL after transplantation: marginal zone NHL, follicular NHL, mantle cell NHL, lymphoplasmocytic NHL (non-WHO lymphoma as LPT) * For HIV-related LPTs and NHLs: LPS * For LPT: tumor EBV status unknown * For immunocompetent NHL: other NHL than diffuse large B cell lymphoma * For lung cancers: small cell lung cancer * Absence of tumor material, blood or saliva samples taken before the start of chemotherapy (except for the specific case of gliomas with certain or possible activation of MAPK and MMR inactivation) * Major under guardianship or curatorship
References
Publications (1)
- DERIVEDAbbar B, Labreche K, Cadranel J, Veyri M, Morin V, Thiam FS, Desire N, Baron M, Guillerm E, Perrier A, Fallet V, Maitre T, Canellas A, Tarantino N, Mze O, Samri A, Dejancourt L, Nakid-Cordero C, Vozy A, Picca A, Touat M, Guihot A, Chouaid C, Mokhtari K, Bielle F, Brocheriou I, Rouvier P, Osorio AR, Buob D, Bouzidi A, Marie Y, Assouad J, Boelle PY, Coulet F, Vieillard V, Spano JP, Autran B. Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLC. J Thorac Oncol. 2025 Jul;20(7):897-911. doi: 10.1016/j.jtho.2025.02.001. Epub 2025 Feb 7. PMID 39923848